Guidelines for Finding Genetic Variants Underlying Human Disease
By Daniel MacArthur and Chris Gunter,
Genomes Unzipped
| 04. 24. 2014
New DNA sequencing technologies are rapidly transforming the diagnosis of rare genetic diseases, but they also carry a risk: by allowing us to see all of the hundreds of “interesting-looking” variants in a patient’s genome, they make it potentially easy for researchers to spin a causal narrative around genetic changes that have nothing to do with disease status. Such false positive reports can have serious consequences: incorrect diagnoses, unnecessary or ineffective treatment, and reproductive decisions (such as embryo termination) based on spurious test results. In order to minimize such outcomes the field needs to decide on clear statistical guidelines for deciding whether or not a variant is truly causally linked with disease.
In a paper in Nature this week we report the consensus statement from a workshop sponsored by the National Human Genome Research Institute, on establishing guidelines for assessing the evidence for variant causality. We argue for a careful two-stage approach to assessing evidence, taking into account the overall support for a causal role of the affected gene in the disease phenotype, followed by an assessment of the probability...
Related Articles
By Jennifer Takhar, Carolyn Wilson-Nash, and Chloe He, BioNews | 06.22.2026
Imagine wanting to have a child and discovering, at every stage, that the system was not designed with you in mind. This is the reality for many LGBTQ+ people in the UK who seek fertility treatment each year.
Our study...
By Carl Zimmer, The New York Times | 06.04.2026
Scientists at Columbia University have edited the DNA of early human embryos with unprecedented accuracy, an achievement that could open the way to babies engineered with particular characteristics.
The prospect has fueled controversy for years. On the one hand, the...
By Alexandre Piquard, Le Monde [cites CGS' Katie Hasson] | 05.22.2026
"If proven to be safe, we believe preventive gene editing could be one of the most important health technologies of the century." This is how Lucas Harrington explained the goal of his company Preventive: to create genetically modified babies. Trying...
By Daniel Shanahan, Los Angeles Review of Books | 05.31.2026
This is the 15th installment in the Legacies of Eugenics series, which features essays by leading thinkers devoted to exploring the history of eugenics and the ways it shapes our present. You can read the first part here. The series...